Table 1.

Demographic characteristics of hemophilia gene therapy survey respondents

Variable	Percentage of respondents (n = 194)
Professional category
Physician	66
PhD/Researcher	13
Registered nurse, advanced practice registered nurse, or physician assistant	7
Technician, scientist, or technologist	5
Health business/medical administration professional	4
Other (including pharmacist; patient advocate; NGO; educator; health economist)	4
Student/Resident	1
Primary clinical focus
Bleeding disorders including hemophilia	39
Thrombosis and hemophilia	28
Hematology	11
Hematology/Oncology	8
Thrombosis/Clotting	7
Other nonclinical (bleeding disorders, FVIII, gene therapy, industry, product development, thrombosis and bleeding disorders, transfusion)	5
Internal medicine	1%
Other clinical (clinical chemistry)	1%
Role in the care of people with hemophilia a
Physician involved in direct patient care	59
Investigator in clinical trials of people with hemophilia	38
Patient education	27
Perform assays/assessments in a specialized coagulation laboratory	22
Basic research related to hemophilia but not related to patient care	20
Other (including nurse coordinator, nurse clinician, industry, administration, health care education, health economics and outcomes research, patient advocacy)	17
Practice setting
Academic medical center	54
Industry	13
Hemophilia treatment center (independent of an academic medical center)	11
Government hospital	9
Other (including nonprofit organization; patient organization; government research center)	7
Hemostasis center	3
Community‐based hospital	2
Outpatient clinic/ambulatory setting	1

Abbreviations: FVIII, factor VIII; NGO, nongovernmental organization.

^aRespondents could select all applicable responses.